RxDoctor Payments DataLook up a doctor →

Candise Love

Acute Care · Port Huron, MINPI 1801102371

Payments from drug & device makers

$14,464in general payments, 2019–2025

Across 619 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Merck$876
  • AbbVie$765
  • Daiichi Sankyo Inc.$534
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$2,396
AstraZeneca(2 entities)45$1,020
Johnson & Johnson53$1,018
Merck35$876
AbbVie23$765
Daiichi Sankyo Inc.25$534
Eisai Inc.28$533
Incyte Corporation20$463
Lilly USA, LLC25$440
Genentech USA, Inc.22$402
Gilead(2 entities)15$348
Takeda Pharmaceuticals U.S.A., Inc.11$345
Sanofi13$294
Astellas Pharma US Inc14$289
Amgen11$235
GSK12$232
Sobi, Inc9$225
Seagen Inc.13$224
E.r. Squibb & Sons, L.L.C.6$220
Exelixis Inc.6$178
AMAG Pharmaceuticals, Inc.9$172
Ipsen Biopharmaceuticals, Inc7$170
EMD Serono, Inc.2$165
ASD Specialty Healthcare, LLC3$164
AVEO Pharmaceuticals, Inc.10$163
Beigene USA, Inc.7$151
Bristol Myers Squibb9$142
Geron Corporation3$137
Servier Pharmaceuticals LLC8$136
Mirati Therapeutics, Inc.7$131
Pfizer6$118
Pharmacyclics LLC, An Abbvie Company7$109
Avyxa Pharma, LLC1$103
Karyopharm Therapeutics Inc.4$102
Deciphera Pharmaceuticals Inc.6$99
Bayer6$91
Genmab U.S., Inc.4$86
Eagle Pharmaceuticals, Inc.2$75
Agios Pharmaceuticals, Inc.3$72
Pharmacosmos Therapeutics Inc.4$71
Apellis Pharmaceuticals, Inc.3$70
Acrotech Biopharma Inc.2$65
Regeneron Healthcare Solutions, Inc.2$64
Sumitomo Pharma America, Inc.3$62
Janssen Scientific Affairs, LLC2$59
Myriad Genetic Laboratories, Inc.3$55
Macrogenics, Inc.2$49
Fresenius Kabi USA, LLC2$45
Stemline Therapeutics Inc.2$45
Azurity Pharmaceuticals, Inc.2$43
Pharmaessentia USA Corporation2$43
Array Biopharma Inc2$40
Taiho Oncology, Inc.2$38
Puma Biotechnology, Inc.2$33
Tactile Systems Technology Inc2$33
Dova Pharmaceuticals2$31
Morphosys, US Inc.2$27
Recordati_rare_diseases_inc.1$26
Rigel Pharmaceuticals, Inc.1$21
Immunogen, Inc.1$21

How this compares

$14,464 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.

See all acute care providers in Michigan →

Medicare billing

Part B allowed, 2024
$15,378
Medicare patients
96
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Port Huron

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →